Hypera S.A. (BST:HM6A)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.46B +18.0% |
| Revenue (ttm) | 1.19B +3.4% |
| Net Income | 184.84M -10.9% |
| EPS | 0.29 -10.7% |
| Shares Out | n/a |
| PE Ratio | 13.31 |
| Forward PE | 8.21 |
| Dividend | 0.16 (4.16%) |
| Ex-Dividend Date | Apr 6, 2026 |
| Volume | n/a |
| Average Volume | 70 |
| Open | 3.780 |
| Previous Close | 3.780 |
| Day's Range | 3.780 - 3.840 |
| 52-Week Range | 2.980 - 4.700 |
| Beta | n/a |
| RSI | 51.20 |
| Earnings Date | Mar 12, 2026 |
About Hypera
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptic... [Read more]
Financial Performance
In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.
Financial numbers in BRL Financial StatementsNews
Brazil's Hypera announces new majority stakeholder group
Brazilian drugmaker Hypera said on Monday that shareholders executed an agreement by which a new control group now holds 53% of share capital.